Understand the source comparison
ARA290: Peptide Comparison
ARA290 Tissue protection via innate repair receptor activation; anti-apoptotic and anti-inflammatory signaling CD131-EPO receptor heterodimer (IRR) Phase II RCTs in diabetic neuropathy and sarcoidosis; 58% responder rate for 30% pain reduction at 8mg daily 4–6
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- ARA290
- Tissue protection via innate repair receptor activation; anti-apoptotic and anti-inflammatory signaling
- CD131-EPO receptor heterodimer (IRR)
- Phase II RCTs in diabetic neuropathy and sarcoidosis; 58% responder rate for 30% pain reduction at 8mg daily
- 4–6 hours SC
- First non-erythropoietic EPO derivative with clinical proof of neuroprotection; limited by short half-life requiring daily dosing
- BPC 157
- Angiogenesis and nitric oxide-mediated tissue repair; modulates growth factor expression
- No defined receptor; proposed VEGFR and FGFR interaction
- Preclinical only; no human RCTs; extensive animal data in tendon/ligament healing
- Strongest preclinical tissue repair profile but zero published human trial data; mechanism poorly characterized
- Thymosin Alpha 1
- Immune modulation via T-cell maturation and dendritic cell activation
- TLR-2 and TLR-9 signaling pathways
- Phase III trials in hepatitis B/C; approved in 35+ countries for immune deficiency
- 2–3 hours SC
- Proven immune enhancer with regulatory approval; distinct from tissue-protective peptides like ARA290
- TB 500
- Actin sequestration and cell migration; upregulates MMP expression and downregulates inflammatory cytokines
- G-actin binding; no classical receptor
- Animal models only; no controlled human trials; widely used in veterinary applications
- 12–15 hours SC
- Longer half-life than ARA290; proposed mechanism plausible but lacks clinical validation in humans
- Erythropoietin (EPO)
- Stimulates erythroid progenitor proliferation; tissue protection at supra-physiologic doses
- EPO receptor homodimer (erythropoiesis) and EPO-R/CD131 heterodimer (tissue protection)
- Extensive clinical use for anemia; tissue-protective effects documented but not approved due to erythropoietic side effects
- 8–12 hours SC/IV
- ARA290 was designed specifically to isolate EPO's tissue-protective effects without hematocrit elevation
- ARA290 occupies a unique position as the only selective innate repair receptor agonist with published human efficacy data in neuropathy. Unlike BPC 157 and TB 500, which remain entirely preclinical in humans despite extensive anecdotal use, ARA290 has completed phase II randomized controlled trials demonstrating statistically significant improvements in objective endpoints like corneal nerve fiber density and quantitative sensory testing. The trade-off is the short half-life requiring daily or near-daily administration, whereas TB 500's longer duration allows less frequent dosing.